Adverse reactions to parenteral lincomycin.

Abstract

Lincomycin use has not been reported exclusively in children and inasmuch as it has been extensively used at our institution, a chart review of 265 patients who received parenteral lincomycin at a dose of 100 mg/kg/day in four divided doses for five days or longer was undertaken. The following conditions were diagnosed: cellulitis, 39%; septic arthritis, 21%; osteomyelitis, 16%; abscess, 13%; lymphadenitis, 9%; and pneumonia, 1%. Cures were achieved in all. The majority of organisms cultured were Staphylococcus aureus and Streptococcus pyogenes. Duration of therapy ranged from five to 63 days, with a mean of 15 days. The lincomycin dose ranged from 75 to 2,400 mg every six hours. The majority of patients received the drug intravenously, but 25.7% received it only intramuscularly. There were no adverse reactions at the administration sites. Only 3% of the patients developed diarrhea, which was not felt to be secondary to the drug. There were no cases of pseudomembranous colitis. Therefore parenteral lincomycin in children appears to be a safe and effective antibiotic when used for infections due to Gram-positive cocci.

• Authors: D D Berry, B H Brouhard, Q T Box
• Journal: Pediatrics (Pediatrics) Vol. 67 Issue 3 Pg. 389-91 (Mar 1981) ISSN: 0031-4005 [Print] United States
• PMID: 7017577 (Publication Type: Journal Article)

Chemical References

• Lincomycin

Topics

• Abscess (drug therapy)
• Adolescent
• Arthritis, Infectious (drug therapy)
• Cellulitis (drug therapy)
• Child
• Child, Preschool
• Eosinophilia (chemically induced)
• Female
• Humans
• Infant
• Infant, Newborn
• Injections, Intramuscular
• Injections, Intravenous
• Lincomycin (administration & dosage, adverse effects, therapeutic use)
• Lymphadenitis (drug therapy)
• Male
• Osteomyelitis (drug therapy)
• Retrospective Studies
• Staphylococcus aureus (isolation & purification)
• Streptococcus pyogenes (isolation & purification)